GH1 and metabolic dysfunction-associated steatotic liver disease: High prevalence of NAFLD among adult hypopituitary patients with GHD as compared to that in the control group (77% vs. 12%)↓ Fibrotic marker concentrations, (p = 0.04)Improvement of histological changes in patients with NASH after GH replacement therapy) Six months after GH replacement therapy, serum liver enzyme concentrations were significantly decreased.